NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
PR Newswire•22/07/2026•08:30 ET
2
Whiz Insights
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program
Get started
Create a free account to read the full story.